Second-Generation Antipsychotics and Metabolic Side Effects in the Canadian Population

Simple item page
atmire.migration.oldid4588
dc.contributor.advisorPringsheim, Tamara
dc.contributor.advisorPatten, Scott
dc.contributor.authorHirsch, Lauren Elizabeth
dc.contributor.committeememberJette, Nathalie
dc.contributor.committeememberBresee, Lauren
dc.date.accessioned2016-08-04T14:57:19Z
dc.date.available2016-08-04T14:57:19Z
dc.date.issued2016
dc.date.submitted2016en
dc.description.abstractThe use of second-generation antipsychotic (SGA) has increased substantially in Canada over the last decade. Though an association has been found between SGAs and metabolic dysfunction in randomized controlled trials (RCTs), this information might not be generalizable to all SGA users. Furthermore, SGA use has been inadequately characterized in the population. This thesis aimed to quantify trends in SGA use and the effect of SGAs on indicators of metabolic dysfunction in the Canadian population through two studies: i) a systematic review the literature on population-based studies of SGA use and their associated metabolic harms, and ii) a cross-sectional analysis of SGA use using the Canadian Health Measures Survey (CHMS). The results of this thesis showed SGA use has tripled in Canada between 2007 and 2013 and confirmed the presence of metabolic dysfunction and poor health in SGA users in the general household population.en_US
dc.identifier.citationHirsch, L. E. (2016). Second-Generation Antipsychotics and Metabolic Side Effects in the Canadian Population (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/27724en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/27724
dc.identifier.urihttp://hdl.handle.net/11023/3163
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectEpidemiology
dc.subjectMedicine and Surgery
dc.subjectMental Health
dc.subjectPublic Health
dc.subject.classificationsecond-generation antipsychoticsen_US
dc.subject.classificationadverse eventsen_US
dc.subject.classificationmetabolic syndromeen_US
dc.titleSecond-Generation Antipsychotics and Metabolic Side Effects in the Canadian Population
dc.typemaster thesis
thesis.degree.disciplineCommunity Health Sciences
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations